Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial
Authors:
- Hugo E. VerdejoHVHugo E. Verdejo
- Adolfo RojasARAdolfo Rojas
- Camila López-CrisostoCLCamila López-Crisosto
- Fernando BaraonaFBFernando Baraona
- Luigi GabrielliLGLuigi Gabrielli
- Vinicius Maracaja-CoutinhoVMVinicius Maracaja-Coutinho
- Mario ChiongMCMario Chiong
- Sergio LavanderoSLSergio Lavandero
- Pablo F. CastroPCPablo F. Castro
Open Access
- 16 February 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1571
Abstract
Background: Pulmonary artery hypertension (PAH) is a chronic and progressive disease. Although current therapy has improved the disease prognosis, PAH has a poor survival rate. The key feature leading to disease progression and death is right ventricular (RV) failure. Methods and results: We assessed the role of trimetazidine, a fatty acid beta-oxidation (FAO) inhibitor, in right ventricular function, remodeling, and functional class in PAH patients, with a placebo-controlled double-blind, case-crossover trial. Twenty-seven PAH subjects were enrolled, randomized, and assigned to trimetazidine or placebo for three months and then reallocated to the other study arm. The primary endpoint was RV morphology and function change after three months of treatment. Secondary endpoints were the change in exercise capacity assessed by a 6 min walk test after three months of treatment and the change in pro-BNP and Galectin-3 plasma levels after three months. Trimetazidine use was safe and well-tolerated. After three months of treatment, patients in the trimetazidine group showed a small but significant reduction of RV diastolic area, and a substantial increase in the 6 min walk distance (418 vs. 438 mt, p = 0.023), without significant changes in biomarkers. Conclusions: A short course of trimetazidine is safe and well-tolerated on PAH patients, and it is associated with significant increases in the 6MWT and minor but significant improvement in RV remodeling. The therapeutic potential of this drug should be evaluated in larger clinical trials.Keywords
Funding Information
- Agencia Nacional de Investigación y Desarrollo (ANID), Chile (15130011, 1181097, 1211270)
This publication has 33 references indexed in Scilit:
- Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycleJournal of Molecular Medicine, 2011
- Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary HypertensionScience Translational Medicine, 2010
- Hypoxia Inducible-Factor1α Regulates the Metabolic Shift of Pulmonary Hypertensive Endothelial CellsThe American Journal of Pathology, 2010
- The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricleJournal of Molecular Medicine, 2009
- Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitationEuropean Journal of Preventive Cardiology, 2008
- Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effectEuropean Heart Journal, 2007
- A new imputation method for small software project data setsJournal of Systems and Software, 2007
- Increased [18F]Fluorodeoxyglucose Accumulation in Right Ventricular Free Wall in Patients With Pulmonary Hypertension and the Effect of EpoprostenolJACC, 2005
- Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertensionJournal of Clinical Investigation, 2005
- Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004